Copy to clipboard 
Zimmer Biomet completed the acquisition of Monogram Technologies, Monogram’s surgeon-guided semi- and fully-autonomous robotic technologies are expected to add new, differentiated capabilities to Zimmer Biomet’s suite of customer-centric technology solutions.
Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty robotic technology, which received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants by early 2027. Additionally, Monogram began conducting a clinical study in July 2025 for the fully autonomous version of its technology.
This acquisition expands Zimmer Biomet’s suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Zimmer Biomet’s portfolio features imageless robotics through its ROSA Robotics platform; a licensed CT-based handheld robot; mixed reality and AI-based navigation; and now Monogram’s semi- and fully autonomous robotics capabilities.
The ROSA platform is rapidly approaching 2,000 installations worldwide and is a leader outside of the United States. Zimmer Biomet is investing in a robust R&D pipeline featuring several new products and software applications expected between now and 2027. This includes ROSA Knee with OptimiZe, which has been submitted to FDA with 510(k) clearance anticipated later this year, and other applications.
“By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings,” said Ivan Tornos, Chairman, President and Chief Executive Officer of Zimmer Biomet. “We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings. I want to personally welcome the Monogram team to Zimmer Biomet, as their talent and technology will accelerate our innovation pipeline, deepen our value to surgeons and strengthen our long-term growth strategy.”
Source: Zimmer Biomet
Zimmer Biomet completed the acquisition of Monogram Technologies, Monogram's surgeon-guided semi- and fully-autonomous robotic technologies are expected to add new, differentiated capabilities to Zimmer Biomet's suite of customer-centric technology solutions.
Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee...
Zimmer Biomet completed the acquisition of Monogram Technologies, Monogram’s surgeon-guided semi- and fully-autonomous robotic technologies are expected to add new, differentiated capabilities to Zimmer Biomet’s suite of customer-centric technology solutions.
Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty robotic technology, which received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants by early 2027. Additionally, Monogram began conducting a clinical study in July 2025 for the fully autonomous version of its technology.
This acquisition expands Zimmer Biomet’s suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Zimmer Biomet’s portfolio features imageless robotics through its ROSA Robotics platform; a licensed CT-based handheld robot; mixed reality and AI-based navigation; and now Monogram’s semi- and fully autonomous robotics capabilities.
The ROSA platform is rapidly approaching 2,000 installations worldwide and is a leader outside of the United States. Zimmer Biomet is investing in a robust R&D pipeline featuring several new products and software applications expected between now and 2027. This includes ROSA Knee with OptimiZe, which has been submitted to FDA with 510(k) clearance anticipated later this year, and other applications.
“By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings,” said Ivan Tornos, Chairman, President and Chief Executive Officer of Zimmer Biomet. “We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings. I want to personally welcome the Monogram team to Zimmer Biomet, as their talent and technology will accelerate our innovation pipeline, deepen our value to surgeons and strengthen our long-term growth strategy.”
Source: Zimmer Biomet
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
